MCA-derived MSC therapy in renal transplant recipients
Phase 1 other active
Quick answer
MCA-derived MSC therapy in renal transplant recipients for Rejection transplanted kidney, BPAR is a Phase 1 program (other) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Rejection transplanted kidney, BPAR
- Phase
- Phase 1
- Modality
- other
- Status
- active